Undisclosed GPR65 agonist / OMass Therap - LARVOL DELTA

OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases (GlobeNewswire) - "OMass Therapeutics...today announces its $100 million (£75.5 million) Series B financing round. The international syndicate of top-tier life science specialists was led by new investors, GV, Northpond Ventures and Sanofi Ventures, with existing investors, Syncona, Oxford Science Enterprises and Oxford University also participating. Proceeds from the financing will be used to advance OMass’s portfolio towards clinical trials. This includes the development of...a GPR65 agonist for the treatment of inflammatory bowel disease..."

Financing • Immunology • Inflammatory Bowel Disease